Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00018109 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)
A Phase 3 study, sponsored by National Center for Research Resources (NCRR).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00018109: Completed Phase 3 study, sponsored by National Center for Research Resources (NCRR).
NCT00018109 is a Phase 3 study that has completed, run by National Center for Research Resources (NCRR). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00018109, a Phase 3 study, has completed, sponsored by National Center for Research Resources (NCRR).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
To establish a collaborative group of clinical trial centers, with standardized equipment and protocols, able to conduct both drug and gene therapy trials in DMD. To evaluate the therapeutic effect of glutamine and creatine monohydrate on muscle strength in children with DMD. To validate the use of QMT (quantitative muscle strength testing) and gait analysis in children with DMD as reliable tools to quantify muscle strength, monitor disease progression and assess therapeutic response.
Interventions
- DRUG glutamine
- DRUG creatine monohydrate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
What the finished NCT00018109 record still lists
NCT00018109 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which glutamine is the first listed.
NCT00018109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00018109 about?
NCT00018109 is a clinical study titled "A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)". To establish a collaborative group of clinical trial centers, with standardized equipment and protocols, able to conduct both drug and gene therapy trials in DMD. To evaluate the therapeutic effect of glutamine and creatine monohydrate on muscle strength in children with DMD. To validate the use of ...
What is the current status of trial NCT00018109?
This trial is currently completed. It is a Phase 3 study.
What interventions are being tested in trial NCT00018109?
The interventions under investigation include: glutamine (DRUG), creatine monohydrate (DRUG).
Who is sponsoring clinical trial NCT00018109?
This trial is sponsored by National Center for Research Resources (NCRR), which has 94 total clinical trials registered on ClinicalTrials.gov.